|
1
|
Gupta N, Hatoum H and Dy GK: First line
treatment of advanced non-small-cell lung cancer - specific focus
on albumin bound paclitaxel. Int J Nanomedicine. 9:209–221.
2014.PubMed/NCBI
|
|
2
|
Zhong R, Han B and Zhong H: A prospective
study of the efficacy of a combination of autologous dendritic
cells, cytokine-induced killer cells, and chemotherapy in advanced
non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5(Suppl 4):
S389–S396. 2013.PubMed/NCBI
|
|
4
|
Hirsh V: Review of the treatment of
metastatic non small cell lung carcinoma: A practical approach.
World J Clin Oncol. 2:262–271. 2011.PubMed/NCBI
|
|
5
|
Fiala O, Pesek M, Finek J, Svaton M,
Sorejs O, Bortlicek Z, Kucera R and Topolcan O: Prognostic
significance of serum tumor markers in patients with advanced-stage
NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res.
36:461–466. 2016.PubMed/NCBI
|
|
6
|
Choi MK, Hong JY, Chang W, Kim M, Kim S,
Jung HA, Lee SJ, Park S, Chung MP, Sun JM, et al: Safety and
efficacy of gemcitabine or pemetrexed in combination with a
platinum in patients with non-small-cell lung cancer and prior
interstitial lung disease. Cancer Chemother Pharmacol.
73:1217–1225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang L, Ren B, Li H, Yu J, Cao S, Hao X
and Ren X: Enhanced antitumor effects of DC-activated CIKs to
chemotherapy treatment in a single cohort of advanced
non-small-cell lung cancer patients. Cancer Immunol Immunother.
62:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelly RJ, Gulley JL and Giaccone G:
Targeting the immune system in non-small-cell lung cancer: Bridging
the gap between promising concept and therapeutic reality. Clin
Lung Cancer. 11:228–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aktipis CA and Nesse RM: Evolutionary
foundations for cancer biology. Evol Appl. 6:144–159. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schürch CM, Riether C and Ochsenbein AF:
Dendritic cell-based immunotherapy for myeloid leukemias. Front
Immunol. 4:4962013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu H, Song J, Yang Z and Zhang X: Effects
of cytokine-induced killer cell treatment combined with FOLFOX4 on
the recurrence and survival rates for gastric cancer following
surgery. Exp Ther Med. 6:953–956. 2013.PubMed/NCBI
|
|
12
|
Linn YC and Hui KM: Cytokine-induced
NK-like T cells: From bench to bedside. J Biomed Biotechnol.
2010:4357452010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma YJ, He M, Han JA, Yang L and Ji XY: A
clinical study of HBsAg-activated dendritic cells and
cytokine-induced killer cells during the treatment for chronic
hepatitis B. Scand J Immunol. 78:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sangha R, Price J and Butts CA: Adjuvant
therapy in non-small cell lung cancer: Current and future
directions. Oncologist. 15:862–872. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Severo M, Gaio R, Lourenço P, Alvelos M,
Bettencourt P and Azevedo A: Indirect calibration between clinical
observers - application to the New York Heart Association
functional classification system. BMC Res Notes. 4:2762011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ribeiro JP, Matuguma SE, Cheng S, Herman
P, Sakai P, D'Albuquerque LA and Maluf-Filho F: Results of
treatment of esophageal variceal hemorrhage with endoscopic
injection of n-butyl-2-cyanoacrylate in patients with Child-Pugh
class C cirrhosis. Endosc Int Open. 3:E584–E589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Yin J, Li T, Huang S, Yan H,
Leavenworth J and Wang X: NK cell-based cancer immunotherapy: From
basic biology to clinical application. Sci China Life Sci.
58:1233–1245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai H, Wang Y, Lu X and Han W: Chimeric
antigen receptors modified T-cells for cancer therapy. J Natl
Cancer Inst. 108:djv4392016.PubMed/NCBI
|
|
19
|
Yu D, Du K, Liu T and Chen G: Prognostic
value of tumor markers, NSE, CA125 and SCC, in operable NSCLC
Patients. Int J Mol Sci. 14:11145–11156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R, Wang G, Zhang N, Li X and Liu Y:
Clinical evaluation and cost-effectiveness analysis of serum tumor
markers in lung cancer. Biomed Res Int. 2013:1956922013.PubMed/NCBI
|
|
21
|
Pujol JL, Molinier O, Ebert W, Daurès JP,
Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D,
Szturmowicz M, et al: CYFRA 21–1 is a prognostic determinant in
non-small-cell lung cancer: Results of a meta-analysis in 2063
patients. Br J Cancer. 90:2097–2105. 2004.PubMed/NCBI
|
|
22
|
Cui Y, Yang X, Zhu W, Li J, Wu X and Pang
Y: Immune response, clinical outcome and safety of dendritic cell
vaccine in combination with cytokine-induced killer cell therapy in
cancer patients. Oncol Lett. 6:537–541. 2013.PubMed/NCBI
|
|
23
|
Mitchell DA and Sampson JH: Toward
effective immunotherapy for the treatment of malignant brain
tumors. Neurotherapeutics. 6:527–538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Zhang W, Zhang B, Yin X and Pang Y:
DC vaccine therapy combined concurrently with oral capecitabine in
metastatic colorectal cancer patients. Hepatogastroenterology.
60:23–27. 2013.PubMed/NCBI
|
|
25
|
Wang M, Shi SB, Qi JL, Tang XY and Tian J:
S-1 plus CIK as second-line treatment for advanced pancreatic
cancer. Med Oncol. 30:7472013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sabado RL and Bhardwaj N: Directing
dendritic cell immunotherapy towards successful cancer treatment.
Immunotherapy. 2:37–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mantia-Smaldone GM, Corr B and Chu CS:
Immunotherapy in ovarian cancer. Hum Vaccin Immunother.
8:1179–1191. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Minidis NM, Mesner O, Agan BK and Okulicz
JF: Delayed-type hypersensitivity (DTH) test anergy does not impact
CD4 reconstitution or normalization of DTH responses during
antiretroviral therapy. J Int AIDS Soc. 17:187992014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Timmermann C: 'Just give me the best
quality of life questionnaire': The Karnofsky scale and the history
of quality of life measurements in cancer trials. Chronic Illn.
9:179–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoos A, Eggermont AM, Janetzki S, Hodi FS,
Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L and Wolchok
J: Improved endpoints for cancer immunotherapy trials. J Natl
Cancer Inst. 102:1388–1397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pandolfi F, Cianci R, Pagliari D, Casciano
F, Bagalà C, Astone A, Landolfi R and Barone C: The immune response
to tumors as a tool toward immunotherapy. Clin Dev Immunol.
2011:8947042011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuanying Y, Lizhi N, Feng M, Xiaohua W,
Jianying Z, Fei Y, Feng J, Lihua H, Jibing C, Jialiang L and
Kecheng X: Therapeutic outcomes of combining cryotherapy,
chemotherapy and DC-CIK immunotherapy in the treatment of
metastatic non-small cell lung cancer. Cryobiology. 67:235–240.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma X, Lin C and Zhen W: Cancer care in
China: A general review. Biomed Imaging Interv J. 4:e392008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kirkwood JM, Butterfield LH, Tarhini AA,
Zarour H, Kalinski P and Ferrone S: Immunotherapy of cancer in
2012. CA Cancer J Clin. 62:309–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thomas AA, Ernstoff MS and Fadul CE:
Immunotherapy for the treatment of glioblastoma. Cancer J.
18:59–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maggi E: T-cell responses induced by
allergen-specific immunotherapy. Clin Exp Immunol. 161:10–18.
2010.PubMed/NCBI
|
